Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

INTRODUCTION: Targeted therapy for NSCLC is rapidly evolving. EGFR-TKIs benefit NSCLC patients with sensitive EGFR mutations and significantly prolong survival. However, 20–30% of patients demonstrate primary resistance to EGFR-TKIs, which leads to the failure of EGFR-TKI treatment. The mechanisms o...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Mol Med
Главные авторы: Sun, Dantong, Zhu, Yan, Zhu, Jingjuan, Tao, Junyan, Wei, Xiaojuan, Wo, Yang, Hou, Helei
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2020
Предметы:
Short Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7329552/
https://ncbi.nlm.nih.gov/pubmed/32611363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10020-020-00193-z
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы